QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$7.04
-0.2%
$7.44
$6.96
$16.84
N/A1.132.49 million shs3.84 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$48.93
+1.3%
$51.25
$47.58
$70.93
$99.17B0.3915.71 million shs10.30 million shs
CSL Limited stock logo
CSLLY
CSL
$86.92
-1.2%
$92.41
$71.51
$105.11
$84.01B0.7330,065 shs59,588 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$726.31
-2.6%
$764.24
$369.76
$800.78
$690.11B0.343.07 million shs3.49 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
-0.21%-3.96%+0.70%-20.90%-58.12%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
+0.98%-1.67%-6.76%-3.61%-30.86%
CSL Limited stock logo
CSLLY
CSL
-1.18%-5.00%-4.55%-9.28%-13.63%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.66%-1.79%-3.47%+18.73%+101.35%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/AN/AN/AN/AN/AN/AN/AN/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.8586 of 5 stars
3.15.03.34.02.51.71.9
CSL Limited stock logo
CSLLY
CSL
0.4835 of 5 stars
0.03.01.70.01.40.01.3
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8323 of 5 stars
2.44.02.54.02.52.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
1.89
ReduceN/AN/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$61.1825.03% Upside
CSL Limited stock logo
CSLLY
CSL
N/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.050.24% Upside

Current Analyst Ratings

Latest BMY, CSLLY, BAYRY, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
3/22/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$850.00
3/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$775.00 ➝ $850.00
3/11/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/7/2024
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$51.55BN/A$3.83 per share1.84$10.44 per shareN/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B2.20$12.74 per share3.84$14.49 per share3.38
CSL Limited stock logo
CSLLY
CSL
$13.31B6.31$3.10 per share28.05$18.48 per share4.70
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.22$7.38 per share98.44$11.44 per share63.49

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
-$3.18B-$0.82N/A4.82N/A-6.31%17.27%5.20%N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B$3.8612.686.921.4417.83%50.95%16.67%4/25/2024 (Confirmed)
CSL Limited stock logo
CSLLY
CSL
$2.19BN/A0.0024.21N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80125.2339.281.6415.36%51.22%9.94%4/30/2024 (Confirmed)

Latest BMY, CSLLY, BAYRY, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/25/2024N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.5050N/A+$4.5050N/AN/AN/A  
3/5/202412/31/2023
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.38$0.50+$0.12$0.63N/A$12.77 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55$1.70+$0.15$2.53$11.19 billion$11.48 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.456.39%N/AN/A N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.404.90%+8.20%62.18%N/A
CSL Limited stock logo
CSLLY
CSL
$1.091.25%N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.72%+15.15%89.66%10 Years

Latest BMY, CSLLY, BAYRY, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/3/2024
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.01914/29/20244/30/20245/13/2024
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
1.15
1.27
0.80
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
1.24
1.43
1.31
CSL Limited stock logo
CSLLY
CSL
N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
CSL Limited stock logo
CSLLY
CSL
0.03%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
CSL Limited stock logo
CSLLY
CSL
N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
99,723N/AN/ANot Optionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.02 billionOptionable
CSL Limited stock logo
CSLLY
CSL
32,000966.51 millionN/ANot Optionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable

BMY, CSLLY, BAYRY, and LLY Headlines

SourceHeadline
Eli Lilly Shares Show Healthy RiseEli Lilly Shares Show Healthy Rise
fxempire.com - April 19 at 4:23 PM
Andrew Hill Investment Advisors Inc. Acquires New Stake in Eli Lilly and Company (NYSE:LLY)Andrew Hill Investment Advisors Inc. Acquires New Stake in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 19 at 12:41 PM
Eli Lilly and Company (NYSE:LLY) Trading Down 2%Eli Lilly and Company (NYSE:LLY) Trading Down 2%
marketbeat.com - April 19 at 12:25 PM
Q1 2026 Earnings Estimate for Eli Lilly and Company (NYSE:LLY) Issued By Zacks ResearchQ1 2026 Earnings Estimate for Eli Lilly and Company (NYSE:LLY) Issued By Zacks Research
marketbeat.com - April 19 at 9:33 AM
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up NowStrong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
investorplace.com - April 19 at 7:30 AM
Zacks Research Comments on Eli Lilly and Companys Q1 2025 Earnings (NYSE:LLY)Zacks Research Comments on Eli Lilly and Company's Q1 2025 Earnings (NYSE:LLY)
americanbankingnews.com - April 19 at 3:32 AM
Fidelis Capital Partners LLC Has $3.55 Million Stake in Eli Lilly and Company (NYSE:LLY)Fidelis Capital Partners LLC Has $3.55 Million Stake in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 18 at 7:04 PM
Eli Lilly and Company (NYSE:LLY)  Shares Down 0.1% Eli Lilly and Company (NYSE:LLY) Shares Down 0.1%
marketbeat.com - April 18 at 2:47 PM
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)
markets.businessinsider.com - April 18 at 2:14 PM
As Zepbound shortage grows, Eli Lilly says no immediate end is in sightAs Zepbound shortage grows, Eli Lilly says no immediate end is in sight
msn.com - April 18 at 2:14 PM
Indias Biocon developing its own version of Wegovy, clinical trial likely next yearIndia's Biocon developing its own version of Wegovy, clinical trial likely next year
finance.yahoo.com - April 18 at 2:14 PM
Big pharma: cautious optimism ahead of earnings season - analystsBig pharma: cautious optimism ahead of earnings season - analysts
proactiveinvestors.com - April 18 at 11:35 AM
Eli Lillys (LLY) Tirzepatide Meets Goals in Sleep Apnea StudiesEli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
zacks.com - April 18 at 9:55 AM
Q1 2025 EPS Estimates for Eli Lilly and Company Reduced by Zacks Research (NYSE:LLY)Q1 2025 EPS Estimates for Eli Lilly and Company Reduced by Zacks Research (NYSE:LLY)
marketbeat.com - April 18 at 6:31 AM
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
fool.com - April 18 at 5:10 AM
Eli Lillys Weight Loss Drug Zepbound Shows Promise In Reducing Sleep ApneaEli Lilly's Weight Loss Drug Zepbound Shows Promise In Reducing Sleep Apnea
markets.businessinsider.com - April 18 at 12:39 AM
Eli Lilly’s weight-loss drug Zepbound might help cure your sleep apneaEli Lilly’s weight-loss drug Zepbound might help cure your sleep apnea
fastcompany.com - April 18 at 12:39 AM
Even more doses of Eli Lillys Zepbound and Mounjaro are officially in a shortage, FDA saysEven more doses of Eli Lilly's Zepbound and Mounjaro are officially in a shortage, FDA says
msn.com - April 18 at 12:39 AM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Daiwa Securities Group Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)Daiwa Securities Group Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 17 at 6:50 PM
These Stocks Are Moving the Most Today: United Airlines, Travelers, J.B. Hunt, Eli Lilly, ASML, Alcoa, and MoreThese Stocks Are Moving the Most Today: United Airlines, Travelers, J.B. Hunt, Eli Lilly, ASML, Alcoa, and More
msn.com - April 17 at 2:39 PM
Eli Lilly and Company (NYSE:LLY)  Shares Down 0.5% Eli Lilly and Company (NYSE:LLY) Shares Down 0.5%
marketbeat.com - April 17 at 12:42 PM
Eli Lillys Weight-Loss Treatment Found To Help Those With Sleep ApneaEli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea
investopedia.com - April 17 at 12:15 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bayer Aktiengesellschaft logo

Bayer Aktiengesellschaft

OTCMKTS:BAYRY
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
CSL logo

CSL

OTCMKTS:CSLLY
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.